数字PCR评估MGMT启动子甲基化联合蛋白表达降低优化转移性结直肠癌患者对烷化剂疗效的预测
本研究回顾性分析四项II期研究中105例经甲基特异性PCR筛选为MGMT启动子阳性的转移性结直肠癌患者,采用免疫组化检测MGMT蛋白表达、甲基-BEAMing检测启动子甲基化百分比。结果显示免疫组化低评分/甲基-BEAMing高水平的患者联合检测与无进展生存和总生存改善相关,提示两种方法联合可优化患者筛选。
要点
- 在MSP筛选的mCRC中,IHC低评分/MB高水平患者进展风险降低87%(p<0.001),死亡风险降低77%(p=0.001)。
- IHC评分与PFS负相关(p<0.001),MB水平与PFS正相关(p=0.004),但两者与OS无关。
核心结论
- 在经MSP筛选为MGMT缺陷的mCRC中,IHC和MB检测可改善烷化剂治疗的临床结局,两者联合可能优化该情境下的患者筛选。
研究设计与样本
- 回顾性分析四项II期研究(替莫唑胺或达卡巴嗪治疗MSP阳性mCRC)的福尔马林固定石蜡包埋肿瘤组织样本,共纳入105例患者,采用IHC检测MGMT蛋白表达、甲基-BEAMing(MB)检测启动子甲基化百分比,并按客观缓解率、无进展生存(PFS)和总生存(OS)汇总分析。
主要发现
- 105例患者中,部分缓解(PR)12例(11.4%),疾病稳定(SD)24例(22.9%),疾病进展(PD)69例(65.7%)。
- PR/SD患者较PD患者IHC评分更低、MB水平更高。
- IHC MGMT表达与PFS负相关(p<0.001),MB水平与PFS正相关(p=0.004),两者均与OS无关。
- 联合两种检测,IHC低/MB高患者进展风险降低87%(p<0.001),死亡风险降低77%(p=0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: O(6)-methylguanine-DNA-methyltransferase (MGMT) is a repair protein, and its deficiency makes tumours more susceptible to the cytotoxic effect of alkylating agents. Five clinical trials with temozolomide or dacarbazine have been performed in metastatic colorectal cancer (mCRC) with selection based on methyl-specific PCR (MSP) testing with modest results. We hypothesised that mitigated results are consequences of unspecific patient selection and that alternative methodologies for MGMT testing such as immunohistochemistry (IHC) and digital polymerase chain reaction (PCR) could enhance patient enrolment. PATIENTS AND METHODS: Formalin-fixed paraffin embedded archival tumour tissue samples from four phase II studies of temozolomide or dacarbazine in MGMT MSP-positive mCRCs were analysed by IHC for MGMT protein expression and by methyl-BEAMing (MB) for percentage of promoter methylation. Pooled data were then retrospectively analysed according to objective response rate, progression-free survival (PFS) and overall survival (OS). RESULTS: One hundred and five patients were included in the study. Twelve had achieved partial response (PR) (11.4%), 24 stable disease (SD; 22.9%) and 69 progressive disease (PD; 65.7%). Patients with PR/SD had lower IHC scores and higher MB levels than those with PD. MGMT expression by IHC was negatively and MB levels positively associated with PFS (p < 0.001 and 0.004, respectively), but not with OS. By combining both assays, IHC low/MB high patients displayed an 87% reduction in the hazard of progression (p < 0.001) and a 77% in the hazard for death (p = 0.001). CONCLUSION: In mCRC selected for MGMT deficiency by MSP, IHC and MB testing improve clinical outcome to alkylating agents. Their combination could enhance patient selection in this setting.
引用
- Sartore-Bianchi A, Pietrantonio F, Amatu A, et al. Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. Eur J Cancer. 2016. PMID: 27997874. doi:10.1016/j.ejca.2016.10.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。